Uno studio per testare diverse dosi di BI 1584862 in persone con una forma distinta di degenerazione maculare legata all'età (AMD) chiamata atrofia geografica
JADE: Studio di fase II in pazienti con atrofia geografica: uno studio di determinazione della dose randomizzato, in doppio cieco, controllato con placebo per valutare l'efficacia e la sicurezza della BI 1584862
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.
Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Arecibo, Porto Rico, 00612
- Emanuelli Research & Development Center
-
-
-
-
Arizona
-
Gilbert, Arizona, Stati Uniti, 85297
- Associated Retina Consultants
-
Phoenix, Arizona, Stati Uniti, 85020
- Associated Retina Consultants, Ltd.
-
Phoenix, Arizona, Stati Uniti, 85050
- Cameron Ria, LLC
-
Scottsdale, Arizona, Stati Uniti, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Beverly Hills, California, Stati Uniti, 90211
- Retina-Vitreous Associates Medical Group
-
Glendale, California, Stati Uniti, 91204
- Global Research Management
-
Huntington Beach, California, Stati Uniti, 92647
- Retina Associates of Southern California
-
Modesto, California, Stati Uniti, 95356
- Retinal Consultants Medical Group, Inc
-
Mountain View, California, Stati Uniti, 94040
- Northern California Retina Vitreous Associates MedicalGroup, Inc.
-
Newport Beach, California, Stati Uniti, 92663
- Eye Research Foundation
-
Poway, California, Stati Uniti, 92064
- Retina Consultants of San Diego
-
Sacramento, California, Stati Uniti, 95825
- Retinal Consultants Medical Group
-
Walnut Creek, California, Stati Uniti, 94598
- Bay Area Retina Associates - Walnut Creek
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80222
- Retina Specialists of Colorado Research, LLC
-
-
Connecticut
-
Greenwich, Connecticut, Stati Uniti, 06830
- Coastal Eye Surgeons
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32605
- Vitreo Retinal Associates - Gainesville
-
Miami, Florida, Stati Uniti, 33143
- MedEye Associates
-
Pinellas Park, Florida, Stati Uniti, 33782
- Eye Associates of Pinellas
-
Stuart, Florida, Stati Uniti, 34994
- East Florida Eye Institute
-
Winter Haven, Florida, Stati Uniti, 33880
- Center for Retina and Macular Disease
-
-
Georgia
-
Augusta, Georgia, Stati Uniti, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Park, Illinois, Stati Uniti, 60304
- Illinois Retina Associates - Oak Park
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40206
- The Eye Care Institute
-
-
Maryland
-
Hagerstown, Maryland, Stati Uniti, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
Columbia, Missouri, Stati Uniti, 65212
- University of Missouri Health System
-
-
New Jersey
-
Teaneck, New Jersey, Stati Uniti, 07666
- NJRetina
-
-
Oregon
-
Eugene, Oregon, Stati Uniti, 97401
- Verum Research, LLC
-
Portland, Oregon, Stati Uniti, 97221
- Retina Northwest
-
Portland, Oregon, Stati Uniti, 97225
- EyeHealth Northwest
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Mid Atlantic Retina - Wills Eye Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29414
- Charleston Neuroscience Institute - Charleston
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Tennessee Retina
-
-
Texas
-
Austin, Texas, Stati Uniti, 78750
- Austin Clinical Research, LLC
-
Beaumont, Texas, Stati Uniti, 77707
- Retina Consultants of Texas - Beaumont
-
Dallas, Texas, Stati Uniti, 75231
- Retina Foundation of the Southwest
-
Plano, Texas, Stati Uniti, 75024
- Red River Research Partners, LLC - Plano
-
San Antonio, Texas, Stati Uniti, 78240
- Retinal Consultants of San Antonio
-
Schertz, Texas, Stati Uniti, 78154
- Retina Consultants of Texas - Schertz
-
The Woodlands, Texas, Stati Uniti, 77384
- Retina Consultants of Texas-The Woodlands-67575
-
-
Virginia
-
Falls Church, Virginia, Stati Uniti, 22042
- Emerson Clinical Research Institute
-
Lynchburg, Virginia, Stati Uniti, 24502
- Piedmont Eye Center
-
-
Washington
-
Bellevue, Washington, Stati Uniti, 98004
- Pacific Northwest Retina
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria:
-
Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:
- If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm^2
- At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
- The foveal center point must not be involved in any atrophic lesion
- Lesion(s) must reside completely within the FAF image
-
Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).
-
Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.
-
Age ≥50 years.
-
Men must be willing and able to use contraception (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. A female participant is eligible if she is not a woman of childbearing potential.
-
Signed informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation
Exclusion criteria:
-
Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.
-
Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.
-
Previously received an investigational medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.
-
Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:
- uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
- clinically significant diabetic retinopathy or maculopathy in the opinion of the investigator
- history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
- anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
- other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
-
Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:
- put the participant at risk because of participation in the study
- influence the results of the study
- cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
-
Known hypersensitivity to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.
-
Active intraocular inflammation in the study eye.
-
Active infectious conjunctivitis in either eye. Further exclusion criteria apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore placebo: BI 1584862 corrispondente al placebo
|
Placebo-matching BI 1584862 |
|
Sperimentale: BI 1584862 dose 1
|
BI 1584862 |
|
Sperimentale: BI 1584862 dose 2
|
BI 1584862 |
|
Sperimentale: BI 1584862 dose 3
|
BI 1584862 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye
Lasso di tempo: Up to week 50.
|
mm is millimeters. |
Up to week 50.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Presenza di TEAES dalla somministrazione del farmaco fino alla settimana 52
Lasso di tempo: Fino alla settimana 52.
|
Fino alla settimana 52.
|
|
|
Variazione rispetto al basale dell'attenuazione parziale come percentuale della zona ellissoidale (EZ) nell'area maculare con spessore <20 microgrammi (μm) fino alla settimana 50 valutata mediante tomografia volumetrica a coerenza ottica (OCT) nell'occhio dello studio
Lasso di tempo: Fino alla settimana 50.
|
Fino alla settimana 50.
|
|
|
Variazione rispetto al basale dell'area di atrofia geografica (GA) trasformata in radice quadrata misurata mediante autofluorescenza del fondo (FAF) alla settimana 50 (espressa in mm) nell'occhio dello studio
Lasso di tempo: Al basale e alla settimana 50.
|
Al basale e alla settimana 50.
|
|
|
Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye
Lasso di tempo: Up to week 50.
|
EZ stands for ellipsoid zone. OCT stands for optical coherence tomography. |
Up to week 50.
|
|
Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye
Lasso di tempo: Up to week 50.
|
GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters. |
Up to week 50.
|
|
Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50
Lasso di tempo: Up to week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
Up to week 50.
|
|
Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye
Lasso di tempo: At baseline and at week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
At baseline and at week 50.
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 1484-0005
- U1111-1309-9115 (Identificatore di registro: WHO International Clinical Trials Registry Platform (ICTRP))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Periodo di condivisione IPD
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Criteri di accesso alla condivisione IPD
For study documents - upon signing of a 'Document Sharing Agreement'.
For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .